Vasopressin antagonists: role in the management of hyponatremia
Karen E Yeates1, A Ross Morton
1Department of Medicine, Queen's University, Kingston, Ont, Canada. yeatesk@post.queensu.ca
Abstract:
Hyponatremia is a common electrolyte disorder associated with potentially serious or life-threatening consequences. Serum osmolality and sodium concentration [Na+] are regulated by thirst, the hormone arginine vasopressin (AVP), and renal water and sodium handling. Hyponatremia is frequently caused by dysregulation of AVP, which accompanies disorders of water retention, such as congestive heart failure (CHF) and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Clinical trials with AVP receptor antagonists have confirmed the important role of AVP in the pathophysiology of hyponatremia and suggest these agents are efficacious in treating hyponatremia associated with SIADH, cirrhosis, and CHF. Acting directly at AVP receptors in the renal tubules, these agents promote aquaresis - the electrolyte-sparing excretion of free water - in patients with hyponatremia. In clinical trials, AVP receptor antagonists have been shown to increase the serum [Na+] and urine output while decreasing urine osmolality.
Related Concept Videos
Antihypertensive Drugs: Potassium-Sparing Diuretics
Antihypertensive Drugs: Action of Diuretics
Physiology of the Genitourinary System III: Urine Concentration and Dilution
Regulation of Sodium and Potassium
Sodium Regulation
Sodium ions make up approximately 90% of extracellular cations, with a normal blood plasma concentration of 136–148 mEq/L. A decrease in blood volume and pressure triggers the release of renin from granular cells in the juxtaglomerular complex (JGC), primarily in...
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Diuretics

